Showing 4041-4050 of 5911 results for "".
- Inflammasome Therapeutics Announces First Patient Dosed in Phase 1 DME Study of the Dual Inflammasome Inhibitor K8https://modernod.com/news/inflammasome-therapeutics-announces-first-patient-dosed-in-phase-1-dme-study-of-the-dual-inflammasome-inhibitor-k8/2482069/Inflammasome Therapeutics announced the first patient has been dosed in a phase 1 study of a novel compound in the treatment of diabetic macular edema (DME). The 24-week study (ClinicalTrials.gov ID NCT05699759) is designed to assess safety and initial evidence of efficacy. Th
- LumiThera Initiates EUROLIGHT Registry Study to Evaluate Long-Term Benefits of PBM Using the Valeda for Dry AMDhttps://modernod.com/news/lumithera-initiates-eurolight-registry-study-to-evaluate-long-term-benefits-of-pbm-using-the-valeda-light-delivery-system-for-dry-amd/2482067/LumiThera announced the initiation of the largest PBM trial ever conducted in patients with dry age-related macular degeneration (AMD). A global registry data collection from patients treated with PBM using the Valeda Light Delivery System has been established with Dendrite Clinica
- Rayner Acquires This AG, Maker of Sophi Phaco Machineshttps://modernod.com/news/rayner-acquires-this-ag-maker-of-sophi-phaco-machines/2482064/Rayner announced that it has entered into a definitive agreement to acquire Swiss-based This AG, the inventor, developer and manufacturer of Sophi phaco emulsification machines. Financial terms of the deal were not disclosed. The acquisition marks a new chapter for R
- Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512 for Dry Eye Diseasehttps://modernod.com/news/alcon-announces-positive-topline-results-from-phase-3-comet-trials-of-ar-15512-a-novel-topical-drug-candidate-for-dry-eye/2482063/Alcon announced positive topline results from the two pivotal phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of dry eye disease (DED). In both COMET-2 and COMET-3, which enrolled more than 93
- Aviceda Announces Topline Data From Part 1 of the Phase 2/3 SIGLEC Trial of GA Drug Candidate AVD-104https://modernod.com/news/aviceda-therapeutics-announces-topline-data-from-part-1-of-the-phase-23-siglec-clinical-trial-for-avd-104-demonstrating-positive-safety-and-early-clinical-efficacy-in-patients-with-geographic-atrophy/2482061/Aviceda Therapeutics announced positive topline data of part 1 of the phase 2/3 SIGLEC trial for AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), showing positive safety and efficacy outcomes which were observed at 3 months after a single
- Aviceda Enrolls First Patient in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of DMEhttps://modernod.com/news/aviceda-enrolls-first-patient-in-phase-2-glyco-clinical-trial-evaluating-avd-104-for-the-treatment-of-dme/2482058/Aviceda Therapeutics announced that it has enrolled the first patient in the GLYCO phase 2 US clinical trial evaluating its lead ophthalmic candidate AVD-104 for the management of diabetic macular edema (DME). AVD-104 is an engineered glycan (sialic acid) nanoparticle that reduces inflammati
- IntRIS Hosts ARCR Macular 2024 Meeting and Presents Interview With FDA’s Dr. Wiley Chambershttps://modernod.com/news/intris-hosts-arcr-macular-2024-meeting-and-presents-interview-with-fdas-dr-wiley-chambers/2482057/The International Retinal Imaging Society (IntRIS) hosted the Atlantic Coast Retina Club (ACRC) Macula 2024, led by K. Bailey Freund, MD. According IntRIS, the ACRC meeting format includes rapid-fire single-case presentations, engaging discussions, and conferences covering diverse retin
- Harrow Launches Dry Eye Drug Vevye in the United Stateshttps://modernod.com/news/harrow-introduces-vevye-in-united-states-for-treatment-of-signs-and-symptoms-of-dry-eye-disease/2482053/Harrow announced that Vevye (cyclosporine ophthalmic solution) 0.1% is now available in the United States. It is indicated for treating the signs and symptoms of dry eye disease (DED). Vevye is the company’s nonpreserved, twice-daily dosed prescription drug based on a water free s
- Nidek Launches Mirante Scanning Laser Ophthalmoscope in the United Stateshttps://modernod.com/news/nidek-launches-mirante-scanning-laser-ophthalmoscope-in-the-united-states/2482052/Nidek announced the commercial launch of the Mirante Scanning Laser Ophthalmoscope (SLO) in the United States. The Mirante is a multimodal fundus-imaging platform that combines high-definition SLO and optical coherence tomography (OCT) with ultra-wide field imaging. The multimodal platf
- EyePoint Begins Phase 2 VERONA Clinical Trial of EYP-1901 to Treat Diabetic Macular Edemahttps://modernod.com/news/eyepoint-begins-phase-2-verona-clinical-trial-of-eyp-1901-to-treat-diabetic-macular-edema/2482049/EyePoint Pharmaceuticals, a company focused on therapeutics for retinal diseases, announced that the first patient has been dosed in the VERONA clinical trial of the company’s EYP-1901 for diabetic macular edema (DME). EYP-1901 is an investigational sustained delivery therapy containing vor